Moderna remains unattractive despite forced Nasdaq-100 index buying: quarterly revenue is $145M against a $782M loss, while shares trade around $200. Citi rates it Sell with an $80 target. x.com 

Moderna has almost 40% downside to its average analyst price target of $119.56, which makes the sudden rush to buy it hard to explain. x.com 

Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com 

Moderna generates one-tenth of Bristol Myers Squibb's revenue, making their nearly equal valuations hard to justify. x.com 

Moderna's cash burn and persistent operating losses make profitable commercialization the central constraint despite promising melanoma results. Its revenue remains too small and uneven to cover development costs, while rising diluted shares weaken financial resilience. x.com 

Moderna looks like a logical play on plague-outbreak concerns, though this is outside areas of expertise. A Russian lab worker's sudden death has raised fears of a plague crisis, per Zero Hedge, with the Trump team monitoring the outbreak, and the stock is acting well. x.com 

Moderna is a stock to bet against. x.com 

Moderna's approaching October 24 data release at a Madrid conference makes some pre-event profit-taking likely. After the release, the stock could be $400, $200 or $40; the outcome is unknown. x.com 

Moderna could rise further with strong call flow showing, but it is getting close to a top expected in late October or early November; take profits on the way up. x.com 

Moderna's data catalyst is done, and it won't get an early stop in RCC. That makes it a good short here, with the story over until at least next summer. x.com